← Atlas Theme · spans 1 topics
Pan-isoform pathway blockades bring targeted oncology to patients lacking specific oncogenic mutations.
By simultaneously neutralizing multiple receptor isoforms and downstream feedback loops, next-generation pan-inhibitors extend targeted cancer therapy to wild-type patient populations historically excluded from precision oncology.
1
Topics it spans
2
Findings citing it
—
Evidence window
The convergence
The same conclusion keeps arriving from across the workspace's research — 1 topics independently instantiate this theme. Filter the evidence by where it came from:
Science & Health
FDA Approves Celcuity's Revtorpyk (Gedatolisib) for PIK3CA Wild-Type Breast Cancer The newly approved therapy targets all PI3K isoforms and mTOR complexes to bring precision treatment to breast cancer patients without PIK3CA mutations.
Science & Health
FDA Approaching July 17 Decision on Celcuity's Gedatolisib as First Targeted Therapy for PIK3CA Wild-Type Breast Cancer A comprehensive pan-isoform pathway block prevents cancer cells from bypassing targeted therapies, extending clinical efficacy to the wild-type population.